What is Huma?
Huma operates at the intersection of artificial intelligence and clinical research, providing a comprehensive suite of digital health solutions. Its core offerings include remote patient monitoring, virtual care infrastructure, and sophisticated data analytics tools that empower hospitals and life sciences organizations to optimize patient outcomes. By facilitating real-time data collection and analysis, Huma enables healthcare providers to transition toward more proactive, personalized care models. The company's platform is engineered to integrate seamlessly into existing health systems, addressing the critical need for scalable, secure, and interoperable digital health architecture in an increasingly complex global medical landscape.
How much funding has Huma raised?
Huma has raised a total of $296M across 5 funding rounds:
Series A
$28M
Series B
$25M
Series C
$130M
Private Equity
$33M
Series D
$80M
Series A (2018): $28M with participation from NWS Holdings
Series B (2019): $25M led by Bayer
Series C (2021): $130M supported by Michael Diekmann, Leaps by Bayer, Nikesh Arora, Hitachi Ventures, Samsung Next, Sony Innovation Fund, Unilever Ventures, and HAT Technology & Innovation Fund
Private Equity (2022): $33M featuring AstraZeneca
Series D (2024): $80M backed by AstraZeneca and Hitachi Ventures
Key Investors in Huma
AstraZeneca
A global, science-led biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines across oncology, cardiovascular, and metabolic disease areas.
Hitachi Ventures
The corporate venture capital arm of Hitachi, focusing on strategic investments in digital, industrial, and healthcare technologies to drive global innovation.
Bayer
A multinational life sciences enterprise with deep expertise in pharmaceuticals and consumer health, actively investing in digital farming and healthcare innovation.
What's next for Huma?
With the successful closure of its latest funding round, Huma is well-positioned to scale its operations and expand its footprint in the international healthcare market. The strategic focus will likely center on enhancing its AI-driven diagnostic capabilities and deepening its integration with major life sciences partners. As the industry shifts toward decentralized clinical trials and remote care, Huma's ability to provide actionable insights from complex datasets will be a key differentiator. Future growth will likely involve further investment in R&D to maintain its competitive edge, alongside potential expansion into new therapeutic areas where digital intervention can significantly improve patient quality of life and operational efficiency for health systems worldwide.
See full Huma company page
